GMAB · Genmab A/S

Genmab A/S disclosed Q1 2026 worldwide net trade sales of DARZALEX (daratumumab), including both intravenous and subcutaneous formulations (DARZALEX FASPRO in the U.S.), totaling USD 3,964 million as reported by Johnson & Johnson. This represents a key revenue driver for Genmab, which receives royalties on these global net sales under its exclusive worldwide license agreement with J&J (legal entity Janssen Biotech, Inc.) for development, manufacturing, and commercialization. U.S. sales contributed USD 2,208 million, while the rest of the world added USD 1,756 million, highlighting strong performance across major markets. DARZALEX remains a cornerstone of Genmab's royalty stream, powering its biotechnology operations focused on antibody medicines for cancer and serious diseases. The announcement underscores the commercial success of this Janssen-partnered asset, with no prior period comparatives provided in the release. Investors should note the forward-looking statement disclaimer, which highlights risks including clinical development, manufacturing, market acceptance, and competitive dynamics that could impact future royalty income.